{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:10:08Z","timestamp":1792285808982,"version":"4.4.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005668","name":"Funda\u00e7\u00e3o de Apoio \u00e0 Pesquisa do Distrito Federal","doi-asserted-by":"publisher","award":["Edital 3\/2016"],"award-info":[{"award-number":["Edital 3\/2016"]}],"id":[{"id":"10.13039\/501100005668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["309439\/2018-3"],"award-info":[{"award-number":["309439\/2018-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["307358\/2017-8"],"award-info":[{"award-number":["307358\/2017-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013994","name":"Sociedade Brasileira de Dermatologia","doi-asserted-by":"publisher","award":["FUNADERM 2016"],"award-info":[{"award-number":["FUNADERM 2016"]}],"id":[{"id":"10.13039\/501100013994","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>American tegumentary leishmaniasis (ATL), which can present as either cutaneous (CL) or mucosal leishmaniasis (ML), is endemic in South America, and first-line antimonial treatments are known for their wide range of adverse effects (AEs). Growing reports of drug resistance increase the urgency of the need for better treatment options. The objective of this pilot clinical trial was to assess the efficacy of and AEs associated with the oral combination of miltefosine and pentoxifylline based on a <jats:italic>post hoc<\/jats:italic> analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A pilot, randomized, open-label clinical trial was performed. The experimental group (M+P) received 50 mg twice a day (BID) miltefosine and 400 mg three times a day (TID) pentoxifylline, and the control group (A+P) received 20 mg Sb+V\/kg\/day intravenously and 400 mg TID pentoxifylline. Patients with ML received treatment for 28 days, and patients with CL received treatment for 20 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-three patients were included: 25 with ML and 18 with CL caused by <jats:italic>L.(V.) braziliensis<\/jats:italic>. AEs were more frequent in the A+P group (p=0.322), and there was a need for treatment interruption due to severe AEs (p=0.027). Patients with CL had a higher chance of achieving a cure (p=0.042) and a higher risk of AEs (p=0.033). There was no difference in the chance of a cure based on the treatment (p=0.058).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this pilot randomized clinical trial, M+P treatment and A+P treatment yielded similar cure rates, and the former was associated with a lower risk of AEs. Future studies with more patients and longer follow-up are recommended.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2021.700323","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T17:07:32Z","timestamp":1625159252000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis"],"prefix":"10.3389","volume":"11","author":[{"given":"Sofia Sales","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Holanda","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna C\u00f4rtes","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgeth de Oliveira Carneiro","family":"da Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Subtil Magalh\u00e3es","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ledice In\u00e1cia de Ara\u00fajo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Shu","family":"Kurisky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro Martins","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimunda Nonata Ribeiro","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1111\/jdv.15440","article-title":"Accuracy of a TaqMan-based Real-Time Polymerase Chain Reaction Combined to a Novy-MacNeal-Nicolle Medium Culture for the Diagnosis of American Tegumentary Leishmaniasis","volume":"33","author":"Bergmann","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1517\/17425255.4.9.1209","article-title":"Treatment of Leishmaniasis With Miltefosine: 2008 Status","volume":"4","author":"Berman","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e04542020","DOI":"10.1590\/0037-8682-0454-2020","article-title":"Estimating Direct Costs of the Treatment for Mucosal Leishmaniasis in Brazil","volume":"54","author":"Carvalho","year":"2021","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"B5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1590\/0037-8682-0463-2017","article-title":"Mucosal Leishmaniasis: Urgent Need for More Research","volume":"51","author":"Carvalho","year":"2018","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1080\/14656566.2019.1609940","article-title":"Current and Emerging Medications for the Treatment of Leishmaniasis","volume":"20","author":"Chakravarty","year":"2019","journal-title":"Expert Opin. Pharmacother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) Guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari","year":"2011","journal-title":"Am. J. Trop. Med. Hygiene"},{"key":"B8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1590\/S0074-02762000000400006","article-title":"Action of Pentoxifylline on Experimental Cutaneous Leishmaniasis Due to Leishmania (Leishmania) Amazonensis","volume":"95","author":"de S\u00e1 Oliveira","year":"2000","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: A Review of its Pharmacology and Therapeutic Efficacy in the Treatment of Leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrobial Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2871","DOI":"10.1371\/journal.pntd.0002871","article-title":"Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia","volume":"8","author":"Fern\u00e1ndez","year":"2014","journal-title":"PloS Negl. Trop. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1128\/JCM.01954-16","article-title":"Field Validation of SYBR Green- and TaqMan-Based Real-Time PCR Using Biopsy and Swab Samples To Diagnose American Tegumentary Leishmaniasis in an Area Where Leishmania (Viannia) Braziliensis is Endemic","volume":"55","author":"Gomes","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1590\/abd1806-4841.20142389","article-title":"Complementary Exams in the Diagnosis of American Tegumentary Leishmaniasis","volume":"89","author":"Gomes","year":"2014","journal-title":"Bras. Dermatol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004834.pub2","article-title":"Interventions for American Cutaneous and Mucocutaneous Leishmaniasis","volume":"2","author":"Gonz\u00e1lez","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005067.pub3","article-title":"Interventions for Old World Cutaneous Leishmaniasis","volume":"4","author":"Gonz\u00e1lez","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005067.pub5","article-title":"Interventions for Old World Cutaneous Leishmaniasis","volume":"12","author":"Heras-Mosteiro","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania Braziliensis in Brazil: A Randomized and Controlled Trial","volume":"4","author":"Machado","year":"2010","journal-title":"PloS Negl. Trop. Dis."},{"key":"B17","first-page":"189","article-title":"Brasil. Minist\u00e9rio Da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis. Manual de vigil\u00e2ncia da leishmaniose tegumentar [recurso eletr\u00f4nico] \/ Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis: il. Edi\u00e7\u00e3o eletr\u00f4nica da 2\u00aa edi\u00e7\u00e3o do livro:","year":"2017","journal-title":"Manual de Vigil\u00e2ncia da Leishmaniose Tegumentar Americana"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0006141","DOI":"10.1371\/journal.pntd.0006141","article-title":"Harmonized Clinical Trial Methodologies for Localized Cutaneous Leishmaniasis and Potential for Extensive Network With Capacities for Clinical Evaluation","volume":"12","author":"Olliaro","year":"2018","journal-title":"PloS Negl. Trop. Dis. Public Library Sci"},{"key":"B19","volume-title":"Leishmanioses: Informe Epidemiol\u00f3gico Nas Am\u00e9ricas","year":"2019"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004834.pub3","article-title":"Interventions for American Cutaneous and Mucocutaneous Leishmaniasis","volume":"8","author":"Pinart","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0006052","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug Resistance and Treatment Failure in Leishmaniasis: A 21st Century Challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e61843","DOI":"10.1371\/journal.pone.0061843","article-title":"Interventions for American Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review Update","volume":"8","author":"Reveiz","year":"2013","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.biopha.2018.09.149","article-title":"Intraspecies Susceptibility of Leishmania (Viannia) Braziliensis to Antileishmanial Drugs: Antimony Resistance in Human Isolates From Atypical Lesions","volume":"108","author":"Rugani","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1590\/0037-8682-0292-2018","article-title":"A Randomized, Open-Label Clinical Trial Comparing the Long-Term Effects of Miltefosine and Meglumine Antimoniate for Mucosal Leishmaniasis","volume":"52","author":"Sampaio","year":"2019","journal-title":"Rev. Soc. Bras. Med. Trop. SBMT"},{"key":"B25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1590\/0037-8682-0202-2013","article-title":"Effectiveness of Miltefosine-Pentoxifylline Compared to Miltefosine in the Treatment of Cutaneous Leishmaniasis in C57Bl\/6 Mice","volume":"47","author":"Santarem","year":"2014","journal-title":"Rev. Soc. Bras. Med. Trop. SBMT"},{"key":"B26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00430-003-0201-2","article-title":"Miltefosine (Impavido): The First Oral Treatment Against Leishmaniasis","volume":"193","author":"Sindermann","year":"2004","journal-title":"Med. Microbiol. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for New World Cutaneous Leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral Miltefosine for Indian Visceral Leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14787210.2018.1436967","article-title":"Safety and Efficacy of Miltefosine Monotherapy and Pentoxifylline Associated With Pentavalent Antimony in Treating Mucosal Leishmaniasis","author":"Ventin","year":"2018","journal-title":"Expert Rev. Anti-infective Ther."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2021.700323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T17:07:37Z","timestamp":1625159257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2021.700323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":29,"alternative-id":["10.3389\/fcimb.2021.700323"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2021.700323","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"article-number":"700323"}}